Rivaroxaban as an effective alternative to warfarin in a patient with atrial fibrillation, thrombophilia, and left atrial appendage thrombus: a case report-Reference-Cited by-同舟云学术

Rivaroxaban as an effective alternative to warfarin in a patient with atrial fibrillation, thrombophilia, and left atrial appendage thrombus: a case report

Published:2017-04-09 Issue:1 Volume:11 Page:
ISSN:1752-1947
Container-title:Journal of Medical Case Reports
language:en
Short-container-title:J Med Case Reports

Author:

Scarano Michele,Casale Matteo,Mantini Cesare,Imbalzano Egidio,Consorti Cristiana,Clemente Daniela,Dattilo Giuseppe

Publisher

Springer Science and Business Media LLC

Subject

General Medicine

Link

http://link.springer.com/content/pdf/10.1186/s13256-017-1249-8.pdf

Reference18 articles.

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics – 2014 update: a report from the American Heart Association. Circulation. 2014;129:e28–292.

2. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893–962.

3. Haastrup P, Rudbæk T, Bove J. Resistance to warfarin in a patient with hereditary thrombophilia. Ugeskr Laeger. 2013;175:2572–3.

4. Pizzi G, Cotruzzola AM, Battaglia V. Thrombophilias and new oral anticoagulants, a safe alternative to warfarin? Int J Cardiol. 2016;220:569–70.

5. Girgis IG, Patel MR, Peters GR, Moore KT, Mahaffey KW, Nessel CC, et al. Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban in Patients with Non-valvular Atrial Fibrillation: Results from ROCKET AF. J Clin Pharmacol. 2014;54:917–27.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PaceMaker lead and atrial thrombosis, a rare event but of high clinical importance;Cor et Vasa;2022-09-01

2. PaceMaker lead and atrial thrombosis, a rare event but of high clinical importance;Cor et Vasa;2022-09-01

3. Atrial fibrillation and thrombophilia. DOAC as a valid alternative? A clinical case;Cor et Vasa;2020-11-01

4. Patent foramen ovale and paradoxical coronary artery embolism: rare event with great clinical relevance;Cor et Vasa;2020-07-29

5. Reccurent thrombus in the gigantic left atrium during effective anticoagulant therapy: case report;BMC Cardiovascular Disorders;2020-02-21